We view the fall in the Advanced Oncotherapry (AVO) share price since last week’s AGM as a good opportunity for investors to accumulate shares. The presentation that accompanied the AGM showed the substantial progress – technical, managerial and with financing – that AVO has made over the last 18 months or so and also that the company remains on track to have the first LIGHT system installed in Harley Street next year. We make no change to our DCF-derived target price other
06 Jul 2016
Buying opportunity
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Buying opportunity
- Published:
06 Jul 2016 -
Author:
Robert Sanders -
Pages:
2
We view the fall in the Advanced Oncotherapry (AVO) share price since last week’s AGM as a good opportunity for investors to accumulate shares. The presentation that accompanied the AGM showed the substantial progress – technical, managerial and with financing – that AVO has made over the last 18 months or so and also that the company remains on track to have the first LIGHT system installed in Harley Street next year. We make no change to our DCF-derived target price other